Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eyub Yasar Akdemir has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Improvements in Treatment Delivery Efficiency for MR-Guided Radiation Therapy: An 8-Year Single-Institution Experience

    by Robert A. Herrera, Sirikorn Unsri, Kathryn E. Mittauer, Rupesh Kotecha, Adeel Kaiser, Matthew D. Hall, Yongsook C. Lee, Yonatan Weiss, Tatiana Bejarano, Eyub Y. Akdemir, et al.

    Purpose: While magnetic resonance-guided radiation therapy (MRgRT) may provide significant clinical advantages, delivery times tend to be longer than other radiation therapy (RT) modalities and published data on these times are limited. We evaluated longitudinal treatment times across our 8-year institutional MRgRT experience. Methods/Materials: A retrospective analysis of patients treated at our institution on a 0.35-Tesla MR-Linac between April 2018 and April 2026 was performed. All fractions were delivered with continuous intrafraction cine-MRI, soft tissue tracking, automatic beam gating, and online adaptive radiation therapy (oART) when indicated. The primary objective was to characterize changes in total in-room time (TIRT), treatment delivery time (TDT), and total adaptive time (TAT). For analysis of efficiency gains, our overall experience was separated into early (2018–2022) and late (2022–2026) periods. Results: A total of 1026 patients, 1203 treatment courses, and 7665 fractions were included. The median age was 69 years (range: 19–94) and the most commonly treated sites by treatment course were pancreas (n = 430; 35.7%), thorax (n = 203; 16.9%), abdominopelvic lymph nodes (n = 181; 15.0%), liver (n = 138; 11.5%), and adrenal gland (n = 83; 6.9%). The median prescription dose was 50 Gy (range: 16.0–76.0) in a median of five fractions (range: 1–36). Breath-hold and stereotactic body radiation therapy (SBRT) were used in 87.9% and 88.5% of treatment courses, respectively. From the early (2018–2022) to late (2022–2026) study period, the proportion of fractions utilizing SBRT (49.9% vs. 81.1%; p < 0.001), oART (32.9% vs. 80.2%; p < 0.001), respiratory gating (75.9% vs. 88.8%; p < 0.001), and elective nodal coverage (61.8% vs. 78.2%; p < 0.001) increased, as did the proportion of pancreatic treatments (20.4% vs. 38.4%; p < 0.001) and the utilization of single-fraction courses (3.4% vs. 10.3%; p < 0.001). Despite this increasing complexity between study periods, median oART TIRT decreased from 67.0 to 48.0 min (28.4% reduction; p < 0.001), driven primarily by a reduction in TAT from 20.0 to 7.0 min, p < 0.001. Pancreatic oART fractions showed the greatest improvement (median TIRT, 70.0 to 47.0 min; p < 0.001). In 2022–2026, 78.1% of oART fractions were completed within 60 min vs. 35.5% in 2018–2022 (p < 0.001). Conclusions: Ablative MRgRT, with or without oART, can often be delivered in 60 min or less, including for mobile and anatomically unfavorable tumors. Future software and hardware advances are expected to further improve MRgRT treatment efficiency.

  • Comprehensive performance testing and external validation of an AI algorithm to detect and segment brain metastases

    by Rupesh Kotecha, Eyub Y Akdemir, Naseem Ud Din, Sreenija Yarlagadda, Mauricio Reyes, Francesco Nitti, Alonso N Gutierrez, D Jay M Wieczorek, Yongsook C Lee, Ranjini Tolakanahalli, et al.

    Background: Artificial intelligence (AI)-based models have shown initial promise in imaging brain metastasis; however, many lack validation against advanced imaging-informed datasets, precluding external validity and limiting widespread adoption. To overcome these limitations, we performed comprehensive performance testing against reference standard metrics and externally validated an AI algorithm. Methods: As part of its FDA-clearance process, performance testing of a previously developed U-Net-based AI model was conducted on a multi-institutional cohort with reference standard established via consensus review by 3 neuroradiologists. External validation was performed on patients imaged with dual sequences (augmented) as well as an open-access dataset (UCSF-BMSR). Evaluation metrics included sensitivity, false positive (FP) rate, positive predictive value (PPV), dice similarity coefficient (DSC), 95% Hausdorff distance, normalized surface distance, and qualitative physician assessment. Results: In the FDA performance testing cohort, the AI algorithm achieved a sensitivity of 90.0% (95% CI: 87.0%-94.0%), DSC of 0.86 (95% CI: 0.83-0.89), and average FP rate of 0.57 lesions. In the augmented and open-access external validation cohorts, a sensitivity of 81.4% (95% CI: 73.7%-89.1%) and 85.2% (95% CI: 83.0%-87.4%) with an average number of 0.22 and 1.19 FP lesions and DSCs of 0.70 (95% CI: 0.66-0.73) and 0.78 (95% CI: 0.77-0.78) were calculated, respectively. In the augmented external validation cohort, 38.5% of contours were rated as requiring major revisions. Conclusion: This AI algorithm demonstrated promising performance via 3 unique datasets. However, given the notable rate of contour revisions, these findings support its clinical role not as an autonomous system but as a human-in-the-loop tool requiring physician oversight.

  • Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006)

    by Ozum Atasoy, Elvan Anadol, Atiye Seda Yar Saglam, Eyub Yasar Akdemir, Yasemin Sengun Coskun, Ece Atak, Sefika Dincer, Duygu Deniz Usta, Aslı Emniyet Sert, Gulnur Take Kaplanoglu, et al.

    Introduction: GLP-1 receptor agonists (GLP-1 RA) are drugs used to treat diabetes by enhancing insulin sensitivity and secretion. Recent studies suggest their potential anti-cancer effects, including anti-inflammatory and antioxidant properties. This study evaluates the combined effects of GLP-1 RAs and radiotherapy (RT) on breast cancer progression in a BALB/c mouse model. Materials and Methods: In this study, BALB/c mice were injected with 4T1 breast cancer cells to induce tumors. The mice were randomly assigned to five groups: control, placebo, GLP-1 RA, RT, and combined GLP-1 RA with RT. Histological and immunohistochemical analyses were performed on the tumor tissues to assess changes in morphology and protein expression related to inflammation and apoptosis. In vitro, cell viability assays were also conducted on 4T1 cells to evaluate the effects of GLP-1 RA and RT. Results: The combination of GLP-1 RA and RT resulted in significant tumor size reduction compared to the other treatment groups. Histological analysis showed improved tissue morphology, with restored healthy appearance in tumors treated with both GLP-1 RA and radiotherapy. Immunohistochemical staining revealed changes in the expression of apoptosis-related proteins. In vitro assays demonstrated that the combined treatment significantly decreased the viability of 4T1 breast cancer cells. Conclusion: This study concludes that the GLP-1 RAs and RT combination enhances tumor control and improves histological outcomes in a breast cancer model. This approach offers a promising strategy for patients with coexisting diabetes and breast cancer, potentially improving treatment efficacy and patient outcomes.


  • Quantifying risk of radiation necrosis: Normal tissue complication probability modeling following stereotactic radiosurgery for small brain metastases in the modern era

    by Sreenija Yarlagadda, Ranjini Tolakanahalli, Yanjia Zhang, Djay J. Wieczorek, Tatiana Bejarano, Yongsook C. Lee, Eyub Akdemir, Matthew D. Hall, Robert H. Press, Evan D. Bander, et al.


  • Importance of 3D-TSE imaging for patients with brain metastasis treated with SRS alone

    by Eyub Y. Akdemir, Joseph DiStefano, Kevin J. Abrams, Charif Sidani, Margaret C. Chaneles, Matthew D. Hall, Robert H. Press, D Jay Wieczorek, Ranjini Tolakanahalli, Alonso N. Gutierrez, et al.


  • Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design

    by Rupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, Can Ilgın, Manmeet S Ahluwalia, Wenya L Bi, Jaishri Blakeley, Karan S Dixit, Ian F Dunn, Evanthia Galanis, et al.

    Background: Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporary analysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalf of the Response Assessment in Neuro-Oncology meningioma group. Methods: PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating the activity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at 6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique with I2 indices. Results: The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI: 22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0% (95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%) and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapy were 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6 and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors. Conclusions: Several studies have reported outcomes in patients with recurrent meningiomas testing a variety of agents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarks for future trials to define efficacy of future investigational therapies.


  • Open Access

    Evolving Trends and Patterns of Utilization of Magnetic Resonance-Guided Radiotherapy at a Single Institution, 2018–2024

    by Robert A. Herrera, Eyub Y. Akdemir, Rupesh Kotecha, Kathryn E. Mittauer, Matthew D. Hall, Adeel Kaiser, Nema Bassiri-Gharb, Noah S. Kalman, Yonatan Weiss, Tino Romaguera, et al.

    Background/Objectives: Over the past decade, significant advances have been made in image-guided radiotherapy (RT) particularly with the introduction of magnetic resonance (MR)-guided radiotherapy (MRgRT). However, the optimal clinical applications of MRgRT are still evolving. The intent of this analysis was to describe our institutional MRgRT utilization patterns and evolution therein, specifically as an early adopter within a center endowed with multiple other technology platforms. Materials/Methods: We retrospectively evaluated patterns of MRgRT utilization for patients treated with a 0.35-Tesla MR-Linac at our institution from April 2018 to April 2024. We analyzed changes in utilization across six annualized periods: Period 1 (April 2018–April 2019) through Period 6 (April 2023–April 2024). We defined ultra-hypofractionation (UHfx) as 5 or fewer fractions with a minimum fractional dose of 5 Gy. Electronic health records were reviewed, and data were extracted related to patient, tumor, and treatment characteristics. Results: A total of 823 treatment courses were delivered to 712 patients treated for 854 lesions. The most commonly treated sites were the pancreas (242 [29.4%]), thorax (172; 20.9%), abdominopelvic lymph nodes (107; 13.0%), liver (72; 8.7%), and adrenal glands (68; 8.3%). The median total prescribed dose of 50 Gy in five fractions (fxs) was typically delivered in consecutive days with automatic beam gating in inspiration breath hold. The median biologically effective dose (α/β = 10, BED10) was 94.4 Gy with nearly half (404, 49.1%) of all courses at a prescribed BED10 ≥ 100 Gy, which is widely regarded as a highly effective ablative dose. Courses in Period 6 vs. Period 1 more often had a prescribed BED10 ≥ 100 Gy (60.2% vs. 41.6%; p = 0.004). Of the 6036 total delivered fxs, nearly half (2643, 43.8%) required at least one fx of on-table adaptive radiotherapy (oART), most commonly for pancreatic tumors (1081, 17.9%). UHfx was used in over three quarters of all courses (630, 76.5%) with 472 (57.4%) of these requiring oART for at least one fraction. The relative utilization of oART increased significantly from Period 1 to Period 6 (37.6% to 85.0%; p < 0.001); a similar increase in the use of UHfx (66.3% to 89.5%; p < 0.001) was also observed. The median total in-room time for oART decreased from 81 min in Period 1 to 45 min in Period 6, while for non-oART, it remained stable around 40 min across all periods. Conclusions: Our institution implemented MRgRT with a priority for targeting mobile extracranial tumors in challenging anatomic locations that are frequently treated with dose escalation, require enhanced soft-tissue visualization, and could benefit from an ablative radiotherapy approach. Over the period under evaluation, the use of high-dose ablative doses (BED10 ≥ 100 Gy), oART and UHfx (including single-fraction ablation) increased significantly, underscoring both a swift learning curve and ability to optimize processes to maximize throughput and efficiency.


  • Efficacy of 3D-TSE sequence-based radiosurgery in prolonging time to distant intracranial failure: A session-wise analysis in a histology-diverse patient cohort

    by Eyub Y Akdemir, Selin Gurdikyan, Muni Rubens, Kevin J Abrams, Charif Sidani, Margaret C Chaneles, Matthew D Hall, Robert H Press, D Jay Wieczorek, Ranjini Tolakanahalli, et al.

    Background: Stereotactic radiosurgery (SRS) for patients with brain metastases (BM) is associated with a risk of distant intracranial failure (DIF). This study evaluates the impact of integrating dedicated 3D fast/turbo spin echo (3D-TSE) sequences to MPRAGE in BM detection and DIF prolongation in a histology-agnostic patient cohort. Methods: The study population included adults treated with SRS from February 2019 to January 2024 who underwent MPRAGE alone or dual sequence with the addition of 3D-TSE starting from February 2020. Median times to DIF were estimated using the Kaplan–Meier method. Results: The 216 study patients who underwent 332 SRS courses for 1456 BM imaged with MPRAGE and 3D-TSE (primary cohort) were compared to a control cohort (92 patients, 135 SRS courses, 462 BM). In the session-wise analysis, the median time to DIF between the cohorts was significantly prolonged in the primary vs. control cohorts (11.4 vs. 6.8 months, P = .029), more pronounced in the subgroups with 1–4 metastases (14.7 vs. 8.1 months, P = .008) and with solitary BM (36.4 vs. 10.9 months, P = .001). While patients relapsing on immunotherapy or targeted therapy did not significantly benefit from 3D-TSE (7.2 vs. 5.7 months, P = .280), those who relapsed on chemotherapy or who were off systemic therapy (including synchronous metastases) exhibited a trend toward longer time to DIF with 3D-TSE integration (14.7 vs. 7.9 months, P = .057). Conclusions: Implementing 3D-TSE sequences into SRS practice increases BM detection across all patients and translates into clinical relevance by prolonging time to DIF, particularly in those with limited intracranial disease and those not receiving central nervous system-active agents.


  • An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice

    by Eyub Yasar Akdemir, Yazmin Odia, Matthew D. Hall, Minesh P. Mehta, Rupesh Kotecha


  • Klinik Radyasyon Onkolojisi El Kitabı

    by Bora Uysal, Neslihan Kurtul, Birsen Yücel, Eda Erdiş, Berna Akkuş Yıldırım, Ömer Yazıcı, Vildan Kaya, Özlem Özkaya Akagündüz, Gözde Yazıcı, Ömür Karakoyun Çelik, et al.